Targeting tumor angiogenesis with histone deacetylase inhibitors

Leigh Ellis, Hans Hammers, Roberto Pili

Research output: Contribution to journalShort survey

166 Citations (Scopus)

Abstract

Solid tumor malignancies including breast, lung and prostate carcinomas are considered to be angiogenesis dependent. Tumor angiogenesis is often mediated by hypoxia secondary to tumor growth or by increased oncogenic signaling. Both mechanisms result in increased hypoxia-inducible factor-1 alpha (HIF-1α) signaling and its transcriptional target vascular endothelial growth factor (VEGF). Critical to HIF-1α signaling are post translational modifications including acetylation mediated by histone acetyltransferases (HATS) and deacetylation by histone deacetylases (HDACs). More recently, HDACs were shown to be up-regulated in response to hypoxia mediating increased HIF-1α signaling. HDAC inhibitors represent a new class of anti-cancer therapeutics which show great promise at inhibiting angiogenesis in pre-clinical animal models and early phase clinical trials. This review will discuss the role of HIF-1α and VEGF influence on tumor angiogenesis and how HDACs play a critical role in HIF-1α transcriptional activity. Furthermore it will also be discussed how targeting HDACs via their inhibition create new avenues in treating solid malignancies by increasing the activity of established and novel therapeutic applications.

Original languageEnglish (US)
Pages (from-to)145-153
Number of pages9
JournalCancer Letters
Volume280
Issue number2
DOIs
StatePublished - Aug 8 2009
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Hypoxia-Inducible Factor 1
Histone Deacetylases
Neoplasms
Vascular Endothelial Growth Factor A
Histone Acetyltransferases
Post Translational Protein Processing
Acetylation
Prostate
Breast
Animal Models
Clinical Trials
Carcinoma
Lung
Therapeutics
Growth

Keywords

  • Angiogenesis
  • Angiogenesis inhibitors
  • Animal models
  • Cancer
  • Clinical trials
  • Combination therapy
  • Gene regulation
  • HDAC
  • HDAC inhibitors
  • HIF-1α
  • mTOR inhibitors
  • Tyrosine kinase inhibitors
  • VGEF

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting tumor angiogenesis with histone deacetylase inhibitors. / Ellis, Leigh; Hammers, Hans; Pili, Roberto.

In: Cancer Letters, Vol. 280, No. 2, 08.08.2009, p. 145-153.

Research output: Contribution to journalShort survey

Ellis, Leigh ; Hammers, Hans ; Pili, Roberto. / Targeting tumor angiogenesis with histone deacetylase inhibitors. In: Cancer Letters. 2009 ; Vol. 280, No. 2. pp. 145-153.
@article{72d9389f1bbe43c79991c62a6a6ffbb6,
title = "Targeting tumor angiogenesis with histone deacetylase inhibitors",
abstract = "Solid tumor malignancies including breast, lung and prostate carcinomas are considered to be angiogenesis dependent. Tumor angiogenesis is often mediated by hypoxia secondary to tumor growth or by increased oncogenic signaling. Both mechanisms result in increased hypoxia-inducible factor-1 alpha (HIF-1α) signaling and its transcriptional target vascular endothelial growth factor (VEGF). Critical to HIF-1α signaling are post translational modifications including acetylation mediated by histone acetyltransferases (HATS) and deacetylation by histone deacetylases (HDACs). More recently, HDACs were shown to be up-regulated in response to hypoxia mediating increased HIF-1α signaling. HDAC inhibitors represent a new class of anti-cancer therapeutics which show great promise at inhibiting angiogenesis in pre-clinical animal models and early phase clinical trials. This review will discuss the role of HIF-1α and VEGF influence on tumor angiogenesis and how HDACs play a critical role in HIF-1α transcriptional activity. Furthermore it will also be discussed how targeting HDACs via their inhibition create new avenues in treating solid malignancies by increasing the activity of established and novel therapeutic applications.",
keywords = "Angiogenesis, Angiogenesis inhibitors, Animal models, Cancer, Clinical trials, Combination therapy, Gene regulation, HDAC, HDAC inhibitors, HIF-1α, mTOR inhibitors, Tyrosine kinase inhibitors, VGEF",
author = "Leigh Ellis and Hans Hammers and Roberto Pili",
year = "2009",
month = "8",
day = "8",
doi = "10.1016/j.canlet.2008.11.012",
language = "English (US)",
volume = "280",
pages = "145--153",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Targeting tumor angiogenesis with histone deacetylase inhibitors

AU - Ellis, Leigh

AU - Hammers, Hans

AU - Pili, Roberto

PY - 2009/8/8

Y1 - 2009/8/8

N2 - Solid tumor malignancies including breast, lung and prostate carcinomas are considered to be angiogenesis dependent. Tumor angiogenesis is often mediated by hypoxia secondary to tumor growth or by increased oncogenic signaling. Both mechanisms result in increased hypoxia-inducible factor-1 alpha (HIF-1α) signaling and its transcriptional target vascular endothelial growth factor (VEGF). Critical to HIF-1α signaling are post translational modifications including acetylation mediated by histone acetyltransferases (HATS) and deacetylation by histone deacetylases (HDACs). More recently, HDACs were shown to be up-regulated in response to hypoxia mediating increased HIF-1α signaling. HDAC inhibitors represent a new class of anti-cancer therapeutics which show great promise at inhibiting angiogenesis in pre-clinical animal models and early phase clinical trials. This review will discuss the role of HIF-1α and VEGF influence on tumor angiogenesis and how HDACs play a critical role in HIF-1α transcriptional activity. Furthermore it will also be discussed how targeting HDACs via their inhibition create new avenues in treating solid malignancies by increasing the activity of established and novel therapeutic applications.

AB - Solid tumor malignancies including breast, lung and prostate carcinomas are considered to be angiogenesis dependent. Tumor angiogenesis is often mediated by hypoxia secondary to tumor growth or by increased oncogenic signaling. Both mechanisms result in increased hypoxia-inducible factor-1 alpha (HIF-1α) signaling and its transcriptional target vascular endothelial growth factor (VEGF). Critical to HIF-1α signaling are post translational modifications including acetylation mediated by histone acetyltransferases (HATS) and deacetylation by histone deacetylases (HDACs). More recently, HDACs were shown to be up-regulated in response to hypoxia mediating increased HIF-1α signaling. HDAC inhibitors represent a new class of anti-cancer therapeutics which show great promise at inhibiting angiogenesis in pre-clinical animal models and early phase clinical trials. This review will discuss the role of HIF-1α and VEGF influence on tumor angiogenesis and how HDACs play a critical role in HIF-1α transcriptional activity. Furthermore it will also be discussed how targeting HDACs via their inhibition create new avenues in treating solid malignancies by increasing the activity of established and novel therapeutic applications.

KW - Angiogenesis

KW - Angiogenesis inhibitors

KW - Animal models

KW - Cancer

KW - Clinical trials

KW - Combination therapy

KW - Gene regulation

KW - HDAC

KW - HDAC inhibitors

KW - HIF-1α

KW - mTOR inhibitors

KW - Tyrosine kinase inhibitors

KW - VGEF

UR - http://www.scopus.com/inward/record.url?scp=67349201377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349201377&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.11.012

DO - 10.1016/j.canlet.2008.11.012

M3 - Short survey

VL - 280

SP - 145

EP - 153

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -